OncoSil Medical has completed three manufacturing validation cycles with manufacturing partner Cyclotek, establishing a scalable Australian manufacturing capability for its OncoSil device as the company progresses towards commercial production, according to an announcement from the medical device manufacturer.
The ASX-listed company said the validation program confirmed the production of more than 50 validation doses of the OncoSil device and marks a key operational milestone in its commercialisation strategy.
Commercial production is expected to begin in the second half of calendar 2026, subject to regulatory inspection and approval.
OncoSil said it invested approximately $2.1 million in specialised production equipment as part of a dedicated Australian manufacturing capability established through its partnership with Cyclotek.
The proprietary manufacturing process has been implemented within Cyclotek’s existing facility at Macquarie University Hospital in Sydney.
Chief executive officer and managing director Nigel Lange said the completed validation program strengthens the company’s production readiness.
“The successful completion of our manufacturing validation program is a significant operational milestone for OncoSil Medical,” Lange said.
“Through our strategic partnership with Cyclotek, we have established a scalable Australian manufacturing capability that combines the efficiency of an experienced manufacturing partner with ownership of our specialised production equipment and proprietary manufacturing process.”
He said the model provides greater control over manufacturing capability, product quality and supply while supporting improved margins and positioning the company to meet future global commercial demand.
“Importantly, completing manufacturing validation substantially de-risks a key component of our commercial strategy by demonstrating that we have a validated production capability ready to support future market demand, subject to regulatory approval,” Lange said.
Under the manufacturing arrangement, Cyclotek provides the production facility and operational manufacturing services, while OncoSil retains ownership of its specialised manufacturing equipment, proprietary production process and associated know-how.
According to the company, the manufacturing platform incorporates validated production processes designed to meet applicable quality and regulatory requirements, including ISO 13485, Therapeutic Goods Administration (TGA) and US Food and Drug Administration (FDA) expectations. Cyclotek is currently completing ISO 13485 certification.
OncoSil also said it has introduced proprietary finished packaging, ampoules and POTs, alongside an expanded specialist logistics network, to support a scalable manufacturing and distribution platform for global commercial supply.
The company said the capital-efficient manufacturing model is intended to improve production economics and gross margins over time while strengthening supply chain resilience and supporting future commercial growth.
It added that the validated manufacturing capability is expected to support expansion into existing and new markets as regulatory approvals and market adoption progress.
The content of this article is based on information supplied by Oncosil Medical Ltd. For more information, please refer to the official company announcement and communications from Oncosil. Please consult a licensed and/or registered professional in this area before making any decisions based on the content of this article.
